Sign in
LVTX Stock Price, Chart, Stats & News
LAVA Therapeutics N.V.
Save
45.77M
Market cap
–
Current P/E
–
Forward P/E
LVTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -391.98% |
Operating margin | -591.70% |
Pretax margin | -452.77% |
Net margin | -466.45% |
Effective tax rate | -3.02% |
ROA | -44.83% |
ROE | -108.07% |
D/E | – |
Interest coverage ratio | -45.85x |
LVTX valuation
P/E | – |
P/S | 9.17x |
P/B | 3.69x |
P/CF | -1.48x |
P/FCF | -1.45x |
P/OCF | -1.48x |
PEG | -0.11x |
EV multiple | -4.36x |
About
LAVA Therapeutics N. V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer. Utilizing its proprietary Gammabody platform, the company engineers innovative bispecific antibodies.
Similar securities
Based on sector and market capitalization
Report issue